share_log

Ladenburg Thalmann Initiates Coverage On Corvus Pharmaceuticals With Buy Rating, Announces Price Target of $2

Ladenburg Thalmann Initiates Coverage On Corvus Pharmaceuticals With Buy Rating, Announces Price Target of $2

拉登堡塔尔曼以买入评级启动对Corvus Pharmicals的报道,宣布目标股价为2美元
Benzinga Real-time News ·  2022/10/07 08:41

Ladenburg Thalmann analyst Aydin Huseynov initiates coverage on Corvus Pharmaceuticals (NASDAQ:CRVS) with a Buy rating and announces Price Target of $2.

拉登堡·塔尔曼分析师艾登·侯赛诺夫以买入评级开始对Corvus Pharmicals(纳斯达克股票代码:CRVS)进行报道,并宣布目标股价为2美元。

声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发